IL6 and Graves disease: Collectively, it is hypothesized that if the anti-FSC antibody has a stimulating ability to promote IL-6 or CXCL10 secretion from FSCs like TSH receptor antibody does in Graves’ disease, a functional impairment of corticotroph may occur, resulting in acquired IAD.